European Pharmaceutical Review

FEBRUARY 22, 2023

Results from the first open-label, single-centre study of RT-101,6 which was conducted in Australia, were reported at the start of 2020. Studies show that persistence and adherence are generally better for oral medications compared with injections. 6 This is in addition to some 1,300 capsules given to animals in preclinical studies.

Food and Drug Administration 105

Food and Drug Administration Manufacturing Safety Pharmaceutical 105

European Pharmaceutical Review

DECEMBER 28, 2023

These efficacy results, combined with the safety profile that allows patients to complete their treatment regimen, are extremely encouraging. The majority of patients experienced only mild to moderate treatment-related adverse events, confirming a well-manageable safety profile. later acquired by Eli Lilly and Company.

Food and Drug Administration 84

Food and Drug Administration Patients Safety Medical science 84

European Pharmaceutical Review

MAY 2, 2023

By collaborating with several stakeholders and authorities, multiple stages of development can take place concurrently to speed up R&D without compromising safety protocols. Dr Mieke Borgs has been Head of Clinical Operations Europe at BeiGene since May 2020. The COVID-19 blueprint has shown a way forward.

Patients 105

Patients Medicine Marketing Medical 105

European Pharmaceutical Review

AUGUST 15, 2024

Second generation BTKi, acalabrutinib, was designed to be more specific against the target to mitigate some of the toxicities associated with ibrutinib and has demonstrated an improved safety profile in head-to-head clinical trial ELEVATE-RR (acalabrutinib vs ibrutinib) but with similar efficacy (non-inferiority trial with hazard ratio (HR)=1.0).

Safety 52

Safety Patients Medical Medicine 52